Dr. Luciano Costa from the University of Alabama at Birmingham introduces this Targeted Oncology Case-Based Peer Perspective presentation on bispecific therapy for relapsed/refractory multiple myeloma.
Bispecific Therapy Following Progression of Multiple Myeloma
Dr. Costa emphasizes that absence of prior BCMA-directed therapy and treatment history represent fundamental elements guiding treatment decisions.
Dr. Costa analyzes efficacy patterns for patients with advanced multiple myeloma after 3-4 prior therapy lines.
Dr. Costa addresses the primary clinician concern regarding BCMA-directed T-cell engagers: infection risk.
Dr. Costa addresses community-based versus academic center care debates for complex patients requiring multiple therapy lines.
Dr. Costa discusses evolution from initial single-arm bispecific experience in heavily pretreated patients to recent earlier-setting data.
Dr. Costa concludes by emphasizing the transformative moment in multiple myeloma therapy, with rapidly increasing agents demonstrating incredible efficacy alongside accelerated newer class development.